Acrux Ltd (ASX: ACR) Share Price and News

Mr Dobinson has been a Director since 1998, was appointed Chairman in January 2006 and then Executive Chairman from July 2012 to October 2014. He is a founder and former CEO of Acrux. Mr Dobinson has a background in investment banking and stockbroking.

Mr Brooke joined the Board in June 2016. He founded GBS Venture Partners Pty Ltd in 1996 and has more than 20 years of venture capital experience. In January 2014, he reduced his involvement in GBS and is now special adviser to the firm and its funds. Mr Brooke was formally President of Medvest Inc., a US-based early-stage venture capital group he founded with Johnson & Johnson. Mr Brooke's experience includes company formation and acquisitions, as well as public listings on the NYSE, NASDAQ and ASX exchanges. Mr Brooke is licensed in clinical medicine by the Medical Board of Victoria, Australia and his postgraduate work was in anaesthetics and intensive care.

Mr Oldham has 20 years of life sciences business development, alliance management and sales and marketing experience in Europe, Asia and Australia. Mr Oldham is the CEO and Managing Director at AdAlta Ltd (ASX: 1AD). AdAlta is a clinical stage biotech company developing an innovative range of new antibody-like drugs. Prior to this, he was Executive Leader of Tijan Ventures, an advisory business focussed on growing life sciences companies through strategic advisory and interim leadership services and acquiring cell and gene therapy assets. He was previously CEO and Managing Director of Cell Therapies Pty Ltd and President of Asia Pacific for Hospira, Inc., having held a variety of senior management roles with Mayne Pharma Ltd prior to its acquisition by Hospira. These roles encompassed the development and commercialisation of generic pharmaceuticals, devices, biologics and cellular therapies. Mr Oldham began his business career as an engagement manager with McKinsey & Company.

Mr Kotsanis is a seasoned executive with over 30 years of experience in the pharmaceutical industry and has significant senior leadership experience across the global pharmaceutical markets. He was formerly the Chief Commercial Officer and a Board Member of Synthon Holding BV, a Dutch based pharmaceutical company with global revenue over EUR250 million. Prior to Synthon, he served as President, Europe, Middle East and Africa, for Hospira and where he was responsible for delivering over US$500 million in annual revenue. Hospira was the global leader in generic injectable pharmaceuticals prior to its acquisition by Pfizer. Mr Kotsanis joined Hospira following its acquisition of Mayne Pharma in 2007, where he had served as President, Asia Pacific. He joined Mayne following their acquisition of FH Faulding in 2001, where he held responsibility for commercial activities of the pharmaceutical business in Australia and New Zealand. Prior to Faulding, Mr Kotsanis held a variety of sales and marketing positions with a German multinational pharmaceutical company over an 11 year period.

Mr Brumley has 30 years' experience as a senior partner of Ernst & Young, Oceania. He has eexperience in IPOs, transactions and audit and has advised and worked with Boards of organisations ranging from some of the largest in Australia to fast growing entrepreneurial and medium sized organisations. Mr Brumley was the Oceania IPO Leader at Ernst & Young and worked with clients listing on the Australian, US, UK and key Asian stock exchanges. He held positions as Biotech Markets Leader, National Leader of Strategic Growth Markets and on the Board of Partners of Ernst & Young. He is a Fellow of Chartered Accountants Australia & New Zealand and is a member of the Australian Institute of Company Directors.

-

-